MedTrace Logo

Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)

NCT01075204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 335

Last updated 2013-02-12

Study results available
· View outcomes & findings →

Summary

The objective is to describe the time to recovery of symptoms (cough, mucus, fever, sore throat, and others), tolerability and compliance of treatment with clarithromycin once daily in patients with upper or lower respiratory tract infections in the routine clinical practice.

Conditions

  • Respiratory Tract Infection

Interventions

DRUG

clarithromycin modified release 500 mg

clarithromycin modified release 500 mg for 7 days

Sponsors & Collaborators

  • Eilaf

    collaborator OTHER

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Mohamed Tahoun, Bachelor · Abbott Laboratories - Saudi Arabia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Egypt
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075204 on ClinicalTrials.gov